Short answer
Protara Therapeutics, Inc. (TARA) filed its Q1 2026 10-Q quarterly report on May 13, 2026 for the quarter ended Mar 31, 2026.
Q1 2026 key financials · XBRL
- Net income
- −$18M
- −49.3% YoY
- EPS (diluted)
- −$0.31
- −6.9% YoY
Source: XBRL data from the Protara Therapeutics, Inc. (TARA) Q1 2026 10-Q on SEC EDGAR. USD.
Protara Therapeutics, Inc. Q1 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $0, unchanged YoY; no current or near-term revenues
- Net loss $17.8M vs $11.9M YoY; operating expenses $19.6M vs $14.1M
- Highest R&D spending TARA-002 NMIBC $5.8M vs $3.6M; lowest IV Choline Chloride $2.2M vs $2.5M
- Cash and securities $177.4M vs $197.9M at December 31; operating cash use $21.3M vs $14.7M YoY
- ADVANCED-2 enrollment expected complete second half 2026; THRIVE-3 interim results expected second half 2026
- Additional capital needed; resources expected sufficient for at least 12 months, with market volatility and elevated interest rates as headwinds
Risk Factors
- No material changes to 10-K risk factors filed March 10, 2026
- Regulatory risk carried forward: compliance with FDA requirements for product development and commercialization
- Operational risk carried forward: dependence on successful clinical development of pipeline products
- Financial risk carried forward: need for additional capital to fund operations and development
- Insider-sale signaling risk: CEO adopted sales arrangement covering 754,054 securities through April 28, 2028
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Protara Therapeutics, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.